Morgan Stanley’s RenovoRx RNXT Stock Holding History

Morgan Stanley’s Portfolio RNXT Stock Details RNXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.17K	Buy	7,102 +5,981	+534%	+$5.79K	﹤0.01%	7043
2025 Q4	$942	Buy	+1,121	New	+$1.12K	﹤0.01%	7383
2023 Q4	–	Sell	-176	Closed	-$234	–	7896
2023 Q3	$234	Hold	176	–	–	﹤0.01%	7374
2023 Q2	$398	Hold	176	–	–	﹤0.01%	7398
2023 Q1	$613	Sell	176 -152	-46%	-$535	﹤0.01%	7411
2022 Q4	$771	Sell	328 -100	-23%	-$191	﹤0.01%	7507
2022 Q3	$1K	Sell	428 -1,200	-74%	-$2.61K	﹤0.01%	7594
2022 Q2	$3K	Sell	1,628 -2,224	-58%	-$4.54K	﹤0.01%	7523
2022 Q1	$11K	Buy	+3,852	New	+$13.5K	﹤0.01%	7379

Other funds holding RNXT

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

NPT

Nixon Peabody Trust Boston, Massachusetts $1.26B AUM 24.14% 1-Year Est. Return

CPIG

Chicago Partners Investment Group Chicago, Illinois $4.48B AUM 19.29% 1-Year Est. Return

Morgan Stanley's RNXT Position: Q1 2026 in Review

Morgan Stanley increased its RenovoRx (RNXT) stake by 534% in Q1 2026, buying an estimated $5.79K and bringing the position to 7,102 shares worth $7.17K. The position accounts for ﹤0.01% of the portfolio, ranked #7043.

Morgan Stanley first reported a position in RNXT in Q1 2022 and has held it in 9 quarters since. The position peaked at $11K in Q1 2022. 31 funds tracked by Wall St. Rank hold RNXT as of Q1 2026.

Morgan Stanley held 7,102 shares of RenovoRx worth $7.17K as of Q1 2026.
Morgan Stanley bought 5,981 RenovoRx shares in Q1 2026, an estimated $5.79K.
RenovoRx made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7043 holding.
Morgan Stanley first reported a position in RenovoRx in Q1 2022 and has held it in 9 quarters since.
Morgan Stanley's RenovoRx position peaked at $11K in Q1 2022.
31 funds tracked by Wall St. Rank held RenovoRx as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.